Key result
High power short duration radiofrequency ablation for atrial fibrillation reduced the recurrence of atrial tachyarrhythmias at 1 year compared to low power long duration (OR 0.49; 95% CI 0.35-0.67).
Why the study?
Whether high power short duration improves the efficacy and safety of AF radiofrequency ablation compared with low power long duration remained controversial based on limited data.
Does high power short duration (HPSD) radiofrequency ablation reduce recurrence of atrial tachyarrhythmias in patients with atrial fibrillation compared to low power long duration (LPLD)?
Meta-Analysis (n=3,255)
Does high power short duration (HPSD) radiofrequency ablation reduce recurrence of atrial tachyarrhythmias in patients with atrial fibrillation compared to low power long duration (LPLD)?
Odds Ratio: 0.49 (95% CI 0.35–0.67)
p-value: p=< .0001
HPSD radiofrequency ablation for atrial fibrillation improves 1-year freedom from atrial tachyarrhythmias, reduces procedural time, and decreases esophageal thermal injury compared to LPLD.
HPSD ablation may be preferred over LPLD for AF to reduce 1-year ATA recurrence; confirms benefit in Level 1 meta-analysis.
Background The high power short duration (HPSD) approach was hoped to further improve the efficacy and safety in radiofrequency ablation of atrial fibrillation (AF), compared with Low power long duration (LPLD). However, the conclusion was controversial based on the previous limited data. The aim of this meta-analysis was to evaluate whether the clinical benefits of HPSD are superior to that of LPLD.Methods The PubMed, OVID, the Cochrane Library, and Elsevier’s ScienceDirect databases were searched for clinical studies to compare HPSD and LPLD approach by simple search strings benefiting to a wider screened scope.Results Fifteen trials with 3255 patients were included in this analysis. Pooled analyses suggested that HPSD was associated with a lower recurrence of atrial tachyarrhythmias (ATAs) at 1-year follow-up (OR: 0.49; 95% CI: 0.35 to 0.67, p < .0001), benefitted from AF recurrence reduced (OR: 0.46; 95% CI: 0.31 to 0.67, p < .0001), rather than atrial tachycardia/atrial flutter (AT/AFL), but similar at 6 months follow-up, with a decreased oesophageal thermal injury (ETI) (OR: 0.48; 95% CI: 0.30 to 0.77, p = .002). Meanwhile, the HPSD approach benefitted to increase first-pass pulmonary vein isolation (FPI) (OR: 0.47; 95% CI: 0.34 to 0.64, p < .00001) and decrease acute pulmonary vein re-isolation (PVR) (OR: 0.45; 95% CI: 0.35 to 0.58, p < .00001), both mainly embodied in left pulmonary veins (PVs). HPSD showed a decreased procedural time (SMD: −0.95; 95% CI: −1.06 to −0.85, p < .00001), ablation number for pulmonary vein isolation (PVI) (SMD: −0.41; 95% CI: −0.58 to −0.24, p < .00001) and fluoroscopy time (SMD: −0.22; 95% CI: −0.32 to −0.12, p < .0001), which benefits from PVI + additional ablation strategy (SMD: −0.33; 95% CI: −0.46 to −0.21, p < .0001).Conclusions The HPSD approach was associated with decreasing post-ablation AF recurrence in the 1-year follow-up, ETI, acute PVR (increasing FPI correspondingly), procedural time, ablation number for PVI and fluoroscopy time, benefitted to improve clinical outcomes and procedural process with improved safety.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) conducted a meta-analysis in Atrial fibrillation (n=3,255). High power short duration (HPSD) radiofrequency ablation vs. Low power long duration (LPLD) radiofrequency ablation was evaluated on Recurrence of atrial tachyarrhythmias (ATAs) at 1-year follow-up (OR 0.49, 95% CI 0.35 to 0.67, p=< .0001). High power short duration radiofrequency ablation for atrial fibrillation reduced the recurrence of atrial tachyarrhythmias at 1 year compared to low power long duration (OR 0.49; 95% CI 0.35-0.67).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: